These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37215491)

  • 1. Explaining declining hip fracture rates in Norway: a population-based modelling study.
    Kjeldgaard HK; Holvik K; Abrahamsen B; Tell GS; Meyer HE; O'Flaherty M
    Lancet Reg Health Eur; 2023 Jul; 30():100643. PubMed ID: 37215491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Total Hip Replacements on the Incidence of Hip Fractures in Norway During 1999-2019. A Norwegian Epidemiologic Osteoporosis Studies (NOREPOS) Study.
    Kjeldgaard HK; Meyer HE; O'Flaherty M; Apalset EM; Dahl C; Emaus N; Fenstad AM; Furnes O; Gjertsen JE; Hoff M; Schei B; Søgaard AJ; Tell GS; Holvik K
    J Bone Miner Res; 2022 Oct; 37(10):1936-1943. PubMed ID: 35877138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: Missed opportunities in fracture prevention.
    Abrahamsen B; Skjødt MK; Vestergaard P
    Bone; 2019 Mar; 120():476-481. PubMed ID: 30583122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology and predictors of fractures associated with osteoporosis.
    Lips P
    Am J Med; 1997 Aug; 103(2A):3S-8S; discussion 8S-11S. PubMed ID: 9302892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the future burden of hip fractures in Norway. A NOREPOS study.
    Hagen G; Magnussen J; Tell G; Omsland T
    Bone; 2020 Feb; 131():115156. PubMed ID: 31760216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Various Anti-Osteoporosis Drugs on All-Cause Mortality After Hip Fractures: A Nationwide Population Study.
    Tai TW; Hwang JS; Li CC; Hsu JC; Chang CW; Wu CH
    J Bone Miner Res; 2022 Aug; 37(8):1520-1526. PubMed ID: 35689432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of hip fractures.
    Kannus P; Parkkari J; Sievänen H; Heinonen A; Vuori I; Järvinen M
    Bone; 1996 Jan; 18(1 Suppl):57S-63S. PubMed ID: 8717549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-varying exposure to anti-osteoporosis drugs and risk of first-time hip fracture: a population wide study within the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS).
    Riska BSL; Gunnes N; Stigum H; Finnes TE; Meyer HE; Omsland TK; Holvik K
    Osteoporos Int; 2023 Aug; 34(8):1369-1379. PubMed ID: 37100950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidemiology of osteoporosis in Japan].
    Iki M
    Clin Calcium; 2012 Jun; 22(6):797-803. PubMed ID: 22653016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of an extensive medication-based comorbidity index (Rx-Risk) in explaining the excess mortality after hip fracture in older Norwegians: a NOREPOS cohort study.
    Holvik K; Hjellvik V; Karlstad Ø; Gunnes N; Hoff M; Tell GS; Meyer HE
    BMJ Open; 2022 May; 12(5):e057823. PubMed ID: 35501100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation.
    Pedersen AB; Heide-Jørgensen U; Sørensen HT; Prieto-Alhambra D; Ehrenstein V
    JAMA Netw Open; 2019 Apr; 2(4):e192416. PubMed ID: 31002319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forecasting the burden of future postmenopausal hip fractures.
    Omsland TK; Magnus JH
    Osteoporos Int; 2014 Oct; 25(10):2493-6. PubMed ID: 24980184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006.
    Abrahamsen B; Vestergaard P
    Osteoporos Int; 2010 Mar; 21(3):373-80. PubMed ID: 19436931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment for osteoporosis in people with beta-thalassaemia.
    Bhardwaj A; Swe KMM; Sinha NK
    Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
    Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.